Completed PHASE2/PHASE3 INTERVENTIONAL NCT00180336

Safety and Efficacy Study of RENEWAL 4 AVT

CONTAK RENEWAL 4 AVT Field Following

Sponsor: Boston Scientific Corporation

Conditions Atrial Fibrillation Atrial Flutter Heart Failure Tachycardia Ventricular Fibrillation

Interventions CRT-D

Updated 5 times since 2017 Last updated: Jun 22, 2007 Started: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Atrial Fibrillation and Atrial Flutter and is currently completed. Boston Scientific Corporation leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston Scientific Corporation

Data source: Boston Scientific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bad Nauheim, Germany